Abstract
Nucleic acid based therapeutics offer the possibility of tailor-made treatment of malignant diseases. For recurrent glioblastoma multiforme (GBM), the most aggressive type of brain tumor, no accepted treatment exists, making therapeutically active nucleic acids a viable option. In this review, current preclinical and clinical studies harnessing the potential of antitumoral nucleic acids for GBM treatment will be considered. These include gene therapy to over-express antitumoral gene products, RNA interference to knock down components that promote tumor progression, and the tumor-targeted delivery of antitumoral double stranded RNA. Vectors applied in GBM for the delivery of nucleic acids will be discussed. These include non-replicating and replicating (oncolytic) viruses, as well as non-viral delivery vectors based on polycations or cationic lipids.
Keywords: Gene therapy, oncolytic virotherapy, poly IC, polyplexes, RNAi, Antisense RNA, RNA Interference, RNA polymerase, helicases, Oncolytic Viruses
Anti-Cancer Agents in Medicinal Chemistry
Title: Nucleic Acid-Based Therapeutics for Glioblastoma
Volume: 11 Issue: 8
Author(s): Alexei Shir, Alexander Levitzki, Ernst Wagner, Shoshana Klein and Manfred Ogris
Affiliation:
Keywords: Gene therapy, oncolytic virotherapy, poly IC, polyplexes, RNAi, Antisense RNA, RNA Interference, RNA polymerase, helicases, Oncolytic Viruses
Abstract: Nucleic acid based therapeutics offer the possibility of tailor-made treatment of malignant diseases. For recurrent glioblastoma multiforme (GBM), the most aggressive type of brain tumor, no accepted treatment exists, making therapeutically active nucleic acids a viable option. In this review, current preclinical and clinical studies harnessing the potential of antitumoral nucleic acids for GBM treatment will be considered. These include gene therapy to over-express antitumoral gene products, RNA interference to knock down components that promote tumor progression, and the tumor-targeted delivery of antitumoral double stranded RNA. Vectors applied in GBM for the delivery of nucleic acids will be discussed. These include non-replicating and replicating (oncolytic) viruses, as well as non-viral delivery vectors based on polycations or cationic lipids.
Export Options
About this article
Cite this article as:
Shir Alexei, Levitzki Alexander, Wagner Ernst, Klein Shoshana and Ogris Manfred, Nucleic Acid-Based Therapeutics for Glioblastoma, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (8) . https://dx.doi.org/10.2174/187152011797378599
DOI https://dx.doi.org/10.2174/187152011797378599 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Enzymes To Die For: Exploiting Nucleotide Metabolizing Enzymes for Cancer Gene Therapy
Current Gene Therapy Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Oncogenic LncRNA CASC9 in Cancer Progression
Current Pharmaceutical Design Dexamethasone Reduces Cell Adhesion and Migration of T47D Breast Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Breast Cancer Stem Cells and Intrinsic Subtypes: Controversies Rage On
Current Stem Cell Research & Therapy Current and Future Drug Treatments for Glioblastomas
Current Medicinal Chemistry Glycerophospholipid Synthesis as a Novel Drug Target Against Cancer
Current Molecular Pharmacology Passive Targeting of Cyclophosphamide-Loaded Carbonate Apatite Nanoparticles to Liver Impedes Breast Tumor Growth in a Syngeneic Model
Current Pharmaceutical Design Cancer Preventive Phytochemicals as Speed Breakers in Inflammatory Signaling Involved in Aberrant COX-2 Expression
Current Cancer Drug Targets Regulation of HIF-1α at the Transcriptional Level
Current Pharmaceutical Design Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to "Work it Out"?
Current Pharmaceutical Design Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier
Current Neuropharmacology Osteopontin as a Potential Therapeutic Target for Ischemic Stroke
Current Drug Delivery The Role of Antiangiogenetic Agents in the Treatment of Breast Cancer
Current Medicinal Chemistry Pharmaceutical Applications of Graphene-based Nanosheets
Current Pharmaceutical Biotechnology Production and Application of Copper Radiopharmaceuticals
Current Radiopharmaceuticals Alkaloids from Cyanobacteria with Diverse Powerful Bioactivities
Mini-Reviews in Medicinal Chemistry The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders
Current Neuropharmacology Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-kinase
Anti-Cancer Agents in Medicinal Chemistry CDK-associated Cullin 1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Human Glioblastoma
Current Cancer Drug Targets